Therapeutic options for the 2019 novel coronavirus (2019-nCoV).Nat Rev Drug Discov. 2020 03; 19(3):149-150.NR
Links
MeSH
Adenosine MonophosphateAlanineAntiviral AgentsBetacoronavirusCOVID-19Coronavirus InfectionsDrug RepositioningHIV InfectionsHepatitis BHepatitis CHumansInfluenza, HumanInterferon-alphaMiddle East Respiratory Syndrome CoronavirusNucleosidesPneumonia, ViralPolyethylene GlycolsProtease InhibitorsRecombinant ProteinsSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19 Drug Treatment
Pub Type(s)
News
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
32127666
Clinical Trial Links
Citation
Li, Guangdi, and Erik De Clercq. "Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV)." Nature Reviews. Drug Discovery, vol. 19, no. 3, 2020, pp. 149-150.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.
Li, G., & De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews. Drug Discovery, 19(3), 149-150. https://doi.org/10.1038/d41573-020-00016-0
Li G, De Clercq E. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150. PubMed PMID: 32127666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
AU - Li,Guangdi,
AU - De Clercq,Erik,
PY - 2020/3/5/pubmed
PY - 2020/3/24/medline
PY - 2020/3/5/entrez
SP - 149
EP - 150
JF - Nature reviews. Drug discovery
JO - Nat Rev Drug Discov
VL - 19
IS - 3
SN - 1474-1784
UR - https://www.unboundmedicine.com/medline/citation/32127666/Therapeutic_options_for_the_2019_novel_coronavirus__2019_nCoV__
DB - PRIME
DP - Unbound Medicine
ER -
Latest evidence on COVID-19 from PubMed, WHO, CDC.
Visit free Relief Central.
Visit free Relief Central.
Try the Free App:
